Geographic Atrophy Pipeline Report 2021: Therapeutic Evaluation, Drug Profiles, Unmet Needs, Prominent Companies

Los Angeles, USA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Geographic Atrophy Pipeline Report 2021: Therapeutic Evaluation, Drug Profiles, Unmet Needs, Prominent Companies 

The growing pipeline of Geographic Atrophy clinical trials boost the treatment scenario. Several major players such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, Roche, and many others are developing therapies for the Geographic Atrophy treatment. 

DelveInsight's, "Geographic Atrophy Pipeline Insight'' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Geographic Atrophy pipeline landscape. It comprises Geographic Atrophy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Geographic Atrophy therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights the inactive Geographic Atrophy pipeline products.  

Some of the significant Geographic Atrophy Pipeline Report Highlights  

• There are currently no approved Geographic Atrophy treatments. Several major players such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, Roche, and many others are developing therapies for the Geographic Atrophy treatment. 
• NGM Biopharmaceuticals is currently conducting the Phase 2 CATALINA study, a multicenter, randomized, double-masked, sham-controlled clinical trial, to assess the safety and efficacy of intravitreal injections (IVT) of NGM621 in patients with Geographic Atrophy secondary to age-related macular degeneration (AMD). 
• NGM completed a multi-centre evaluation of NGM621 in an open-label, single-dose, and multiple-dose escalation study in participants with Geographic Atrophy Secondary to Age-related Macular Degeneration (NCT04014777).
  
  

Request for sample pages @ Geographic Atrophy Pipeline

Geographic Atrophy, also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration leading to the progressive and irreversible loss of the retina that can result in a loss of visual function over time. 

Currently, there are no approved treatments for Geographic Atrophy; hence they must be regularly followed by an ophthalmologist so that if patients develop neovascular AMD, they can be treated. 

Geographic Atrophy Pipeline Therapeutics

• NGM621 by NGM Biopharmaceuticals

NGM621 is a humanized IgG1 monoclonal antibody engineered to prohibit the activity of complement C3 with the treatment goal of diminishing disease progression in Geographic Atrophy patients, and with the potential for every eight-week dosing without pegylation. In preclinical models, NGM621's high-affinity binding to C3 has demonstrated the potential for potent C3 inhibition. Phase I results have shown that NGM621 was well tolerated, with no patients experiencing severe adverse events (SAEs), drug-related adverse events (AEs), intraocular inflammation, endophthalmitis, or choroidal neovascularization (CNV). 

For further product profiles, request @ Geographic Atrophy Pipeline Landscape

Scope of Geographic Atrophy Pipeline Drug Insight  

• Coverage: Global 
• Major Players: 50+ Key Players
• Prominent Players: Apellis Pharmaceuticals, NGM Biopharmaceuticals, Roche, and many others.  
• Key Drugs Profiles: 50+ Products
• Phases:  
  • Geographic Atrophy Therapies Late-stage (Phase III)  
  • Geographic Atrophy Therapies (Phase II)
  • Geographic Atrophy Therapies (Phase I) 
  • Geographic Atrophy Therapies Pre-clinical stage and Discovery candidates 
  • Discontinued and Inactive candidates 

• Molecule Types:  
  • Small molecule
  • Gene therapy  
  • Stem cell therapy  

• Mechanism of Action:
  • Protease inhibitors 
  • Immunomodulatory 
  • Multiple kinase inhibitor

• Route of Administration:
  • Oral
  • Inhalation 
  • Subcutaneous 
  • Intravenous

• Targets:
  • Protease
  • Immune System
  • Multiple kinases 

• Product Types:
  • Monotherapy
  • Combination 



Key Questions regarding Current Geographic Atrophy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report    

• What are the current options for Geographic Atrophy treatment?
• How many companies are developing therapies for the treatment of Geographic Atrophy? 
• How many Geographic Atrophy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Geographic Atrophy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Geographic Atrophy market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Geographic Atrophy?  
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Geographic Atrophy therapies? 
• What are the key designations that have been granted for the emerging therapies for Geographic Atrophy? 
• How many patents are granted and pending for the emerging therapies for the treatment of Geographic Atrophy? 

Table of Contents 

Get customized pipeline report @  Geographic Atrophy Pipeline Scenario 

View Related Reports 

• Geographic Atrophy Market Analysis 

DelveInsight's Geographic Atrophy (GA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

• Geographic Atrophy Epidemiology Forecast Analysis 

DelveInsight's Geographic Atrophy (GA) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Geographic Atrophy.

• Endocarditis Market Analysis 

DelveInsight's Endocarditis disease Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

• Community-Acquired Bacterial Pneumonia Market Analysis 

DelveInsight' s Community-Acquired Bacterial Pneumonia (CABP) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

• Ambulatory Arrhythmia monitoring Devices Market Analysis 

Ambulatory Arrhythmia Monitoring Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Ambulatory Arrhythmia Monitoring Devices.

• Neuroendoscopy Market Analysis 

Neuroendoscopy Market Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Neuroendoscopy Market and the historical and forecasted epidemiology.

• Blood Glucose Monitoring Systems Market 

Blood Glucose monitoring systems Market Insights, Competitive Landscape and Market Forecast-2025 report deliver an in-depth understanding of Blood Glucose monitoring systems.

• Arteriotomy Closure Devices Market Analysis 

Arteriotomy Closure Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Arteriotomy Closure Devices and the historical and forecasted epidemiology.

• Coronary Pressure Market Analysis 

Coronary Pressure Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Coronary Pressure and the historical and forecasted epidemiology.

• Bone Grafts and Substitutes Market Analysis 

Bone Grafts and Substitutes Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Bone Grafts and Substitutes and the historical and forecasted epidemiology.

• Peak Flow Meters Market Analysis 

Peak Flow Meters Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Peak Flow Meters and the historical and forecasted epidemiology.

• Chemotherapy-Induced Peripheral Neuropathy Market  

DelveInsight' s CIPN - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

• Neurofibromatosis 2 Market 

DelveInsight' s Neurofibromatosis 2 - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

• Bronchopulmonary Dysplasia Market Analysis 

DelveInsight' s Bronchopulmonary Dysplasia - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

• Narcolepsy Market Analysis 

DelveInsight' s Narcolepsy - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  

Contact Us:



Shruti Thakur 
info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com